These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1433215)

  • 21. 4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.
    Carceller E; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1992 Feb; 35(4):676-83. PubMed ID: 1542094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
    Trova MP; Wissner A; Carroll ML; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Kohler CA
    J Med Chem; 1993 Mar; 36(5):580-90. PubMed ID: 8496938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel class of platelet activating factor (PAF) antagonists. I. Synthesis and structure-activity studies on PAF-sulfonamide isosteres.
    Tsuri T; Haga N; Matsui T; Kamata S; Kakushi H; Uchida K
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):75-84. PubMed ID: 1605805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
    Wissner A; Carroll ML; Green KE; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Wrenn S; Kohler CA
    J Med Chem; 1992 May; 35(9):1650-62. PubMed ID: 1578493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.
    Wichrowski B; Jouquey S; Broquet C; Heymans F; Godfroid JJ; Fichelle J; Worcel M
    J Med Chem; 1988 Feb; 31(2):410-5. PubMed ID: 3339611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.
    Serradji N; Bensaid O; Martin M; Sallem W; Dereuddre-Bosquet N; Benmehdi H; Redeuilh C; Lamouri A; Dive G; Clayette P; Heymans F
    Bioorg Med Chem; 2006 Dec; 14(23):8109-25. PubMed ID: 16893650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
    Yamada T; Tomioka K; Saito M; Horie M; Mase T; Hara H; Nagaoka H
    Arch Int Pharmacodyn Ther; 1990; 308():123-36. PubMed ID: 2099131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disubstituted tetrahydrofurans and dioxolanes and PAF antagonists.
    Bartrolí J; Carceller E; Merlos M; García-Rafanell J; Forn J
    J Med Chem; 1991 Jan; 34(1):373-86. PubMed ID: 1992139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
    Carceller E; Salas J; Merlos M; Giral M; Ferrando R; Escamilla I; Ramis J; García-Rafanell J; Forn J
    J Med Chem; 2001 Aug; 44(18):3001-13. PubMed ID: 11520209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J
    J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
    Serradji N; Bensaid O; Martin M; Kan E; Dereuddre-Bosquet N; Redeuilh C; Huet J; Heymans F; Lamouri A; Clayette P; Dong CZ; Dormont D; Godfroid JJ
    J Med Chem; 2000 Jun; 43(11):2149-54. PubMed ID: 10841793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Derivatives of 2-methylenepropane-1,3-diol as new antagonists of platelet activating factor.
    Grue-Sørensen G; Nielsen IM; Nielsen CK
    J Med Chem; 1988 Jun; 31(6):1174-8. PubMed ID: 3373485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and modeling of new platelet-activating factor antagonists. 2. Synthesis and biological activity of 1,4-bis-(3',4',5'-trimethoxybenzoyl)-2-alkyl and 2-alkyloxymethylpiperazines.
    Tavet F; Lamouri A; Heymans F; Dive G; Touboul E; Blavet N; Godfroid JJ
    J Lipid Mediat Cell Signal; 1997 Jan; 15(2):145-59. PubMed ID: 9034961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma.
    Paris D; Cottin M; Demonchaux P; Augert G; Dupassieux P; Lenoir P; Peck MJ; Jasserand D
    J Med Chem; 1995 Feb; 38(4):669-85. PubMed ID: 7861415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents.
    Merlos M; Gómez LA; Giral M; Vericat ML; García-Rafanell J; Forn J
    Br J Pharmacol; 1991 Dec; 104(4):990-4. PubMed ID: 1810607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.